Background and Aims
While effective in the treatment of eosinophilic esophagitis (EoE) in children, limited data exists on long-term safety and efficacy of swallowed topical corticosteroids.. We investigated if long-term use of swallowed fluticasone in children with EoE leads to sustained reduction in esophageal eosinophils, and endoscopic and clinical improvement.
Methods
In an open-label, prospective, single center study, we offered pediatric patients with active EoE fluticasone 2 puffs to swallow twice a day (strengths in μg/puff: 2–4 years: 44, 5–11 years: 110, ≥12 years: 220). Clinical, endoscopic and histological assessments were performed at baseline and shortly after therapy. If histological remission was seen, fluticasone was continued with clinical follow-ups every 4 months, and endoscopic and histological follow-ups yearly. Clinical scores were derived from 8 symptoms (abdominal pain, nausea, vomiting, regurgitation, chest pain, dysphagia, food impaction and early satiety). Endoscopic scores were derived from 6 features (rings, exudates, furrows, edema, stricture and shearing). Scores were expressed as ratio (features present/total). In addition to peak eosinophils/HPF (primary outcome), histological features (eosinophilic microabscesses, degranulation, superficial layering, basal zone hyperplasia, dilated intercellular spaces and lamina propria fibrosis) were assessed. Median clinical and endoscopic scores and individual histologic features were compared over 4 time intervals: <4 months, 4–12 months, 13–24 months and >24 months. Growth and adverse effects were monitored.
Results
We enrolled 54 patients, 80% male, median age 6.5 years (range 2–17 years), 85% atopic (57% asthma, 68% allergic rhinitis, 31% atopic dermatitis) and 74% with food allergy. Mean follow-up was 20.4 months, the longest being 68 months (5.7 years). Esophageal eosinophils counts significantly decreased (median peak eosinophils/HPF at baseline 72, <4 months: 0.5, 4–12 months: 1.75, 13–24 months: 10, and >24 months: 12, all p<0.01). All histological features significantly decreased from baseline to all follow-up time points (all p<0.01). Lamina propria fibrosis significantly decreased (% patients with fibrosis at baseline 92, <4 months: 41, 4–12 months: 50, 13–24 months: 45, and >24 months: 39, all p<0.01). Endoscopic features improved (score at baseline 0.37, <4 months: 0.17, 4–12 months: 0.17, 13–24 months: 0, and >24 months: 0.1, all p<0.01 except at >24 months: p<0.05). Symptoms improved (score at baseline 0.22, <4 months: 0, 4–12 months: 0.11, 13–24 months: 0.11, and >24 months: 0.11, all p<0.05 except at >24 months: p=0.05). Asymptomatic esophageal candidiasis was seen in 3 children but resolved with anti-fungal therapy. Height and weight Z-scores followed expected growth curves.
Conclusion
We demonstrate that swallowed fluticasone is effective as a long-term maintenance therapy for children with EoE, without growth impediment or serious side effects.